World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
22941
World Ranking
17133
National Ranking
8583

David J. Straus publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David J. Straus sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 423 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David J. Straus D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David J. Straus sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David J. Straus is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with particular attention to pathology and forensic medicine, oncology, pulmonary and respiratory medicine, genetics, and neurology.

The scientist's work covers various specialized topics, including:

  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Cutaneous lymphoproliferative disorders research

David J. Straus has contributed to a significant number of publications in several well-known medical and oncology journals. The frequent publication venues include:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Recent papers authored or co-authored by Straus illustrate involvement in clinical trials and lymphoma studies. Notable publications include:

  • "Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma," 2022, published in New England Journal of Medicine
  • "Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups," 2020, published in Blood Cancer Journal
  • "Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma," 2021, published in Journal of Clinical Oncology
  • "Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial," 2021, published in The Lancet Haematology

The scientist has collaborated frequently with several co-authors, reflecting a network of partnerships within the oncology research community. Frequent collaborators include Ariela Noy, Andrew D. Zelenetz, Matthew J. Matasar, Alison J. Moskowitz, and Steven M. Horwitz.

Best Publications

  • Molecular Basis of T Cell Inactivation by CTLA-4

    Kyung Mi Lee;Ellen Chuang;Matthew Griffin;Roli Khattri

  • Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

    Owen A. O'Connor;John Wright;Craig Moskowitz;Jamie Muzzy

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data

    Jeffrey J. Gaynor;Erick J. Feuer;Claire C. Tan;Danny H. Wu

  • A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

    Craig H. Moskowitz;Stephen D. Nimer;Andrew D. Zelenetz;Tania Trippett

  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

    Tarun Kewalramani;Andrew D. Zelenetz;Stephen D. Nimer;Carol Portlock

  • Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection

    Lawrence D. Kaplan;David J. Straus;Marcia A. Testa;Jamie Von Roenn

  • Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma

    Craig H. Moskowitz;Heiko Schöder;Julie Teruya-Feldstein;Camelia Sima

  • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

    David J. Straus;Carol S. Portlock;Jing Qin;Jane Myers

  • Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

    Paul A. Hamlin;Andrew D. Zelenetz;Tarun Kewalramani;Jing Qin

  • Regulation of PAK Activation and the T Cell Cytoskeleton by the Linker Protein SLP-76

    Juliane Bubeck Wardenburg;Rajita Pappu;Jia-Ying Bu;Bruce Mayer

  • AIDS-related lymphoid neoplasia. The Memorial Hospital experience.

    Dennis A. Lowenthal;David J. Straus;Susanne Wise Campbell;Jonathan W. M. Gold

  • Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

    Lee Ratner;Jeannette Lee;Shenghui Tang;David Redden

  • Primary gastrointestinal lymphoma: A 30‐year review

    Daniel N. Weingrad;Jerome J. Decosse;Paul Sherlock;David Straus

  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

    Craig H. Moskowitz;Matt J. Matasar;Andrew D. Zelenetz;Stephen D. Nimer

  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

    Oliver W. Press;Oliver W. Press;Hongli Li;Heiko Schöder;David J. Straus

  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

    Alison J. Moskowitz;Heiko Schöder;Joachim Yahalom;Susan J. McCall

  • Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.

    V A Miller;F M Benedetti;J R Rigas;A L Verret

  • Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.

    S C Gulati;B Shank;P Black;J Yopp

  • Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

    H. Miles Prince;Madeleine Duvic;Ann Martin;Wolfram Sterry

Frequent Co-Authors

Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
Craig H. Moskowitz
Craig H. Moskowitz University of Miami
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Joachim Yahalom
Joachim Yahalom Memorial Sloan Kettering Cancer Center
Heiko Schöder
Heiko Schöder Memorial Sloan Kettering Cancer Center
Bayard D. Clarkson
Bayard D. Clarkson Memorial Sloan Kettering Cancer Center
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Miguel-Angel Perales
Miguel-Angel Perales Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider studying Medicine in the USA, it’s important to explore related online degrees and alternative career pathways within healthcare. Many students choose to pursue nursing or advanced practice options either as first steps or as rewarding careers of their own.

If cost and flexibility are your priorities, there are affordable nursing programs online that allow you to earn a nursing degree from home while balancing other commitments. For registered nurses seeking to expand their skills and improve job prospects, enrolling in affordable rn to bsn programs offers a streamlined path to a bachelor’s degree.

Those with a non-nursing background who wish to enter the nursing field quickly should consider direct entry online msn programs. These programs are designed for motivated individuals to earn a master’s degree efficiently.

Finally, experienced nurses looking to advance into leadership, education, or research roles can benefit from an online nursing doctorate. Whichever path you choose, online programs offer flexibility, affordability, and a wide range of career opportunities in healthcare.

Best Scientists Citing David J. Straus

Trending Scientists

Recently Published Articles